Results 11 to 20 of about 49,427 (236)

Myeloproliferative neoplasms

HemaSphere, 2018
Myeloproliferative neoplasms (MPNs) - Pathogenesis of the MPNs - Polycythaemia vera (PV) - Natural history of PV - Management of PV - Secondary erythrocytosis - Relative erythrocytosis - Idiopathic erythrocytosis - Essential thrombocythaemia - Reactive thrombocytosis - Primary myelofibrosis - Chronic neutrophilic leukaemia - Eosinophilic syndromes and ...
Jean-Jacques Kiladjian
doaj   +3 more sources

Myeloproliferative neoplasms

HemaSphere, 2019
Nick Cross, (Coordinating Author)
doaj   +4 more sources

Diagnostic reassessment in myeloproliferative neoplasms: the value of functional iron parameters and JAK2 allelic burden. [PDF]

Ann Hematol
González-Resina R, España-Fernández de Valderrama S, Montañés Á, Recasens V, Caballero G.   +4 more
europepmc   +3 more sources

Myeloproliferative neoplasms [PDF]

Clinical Medicine, 2013
The myeloproliferative neoplasms that are associated with the JAK2 mutation are a heterogeneous group of disorders. The additional mutations that result in the clinical phenotype are still the subject of research. As more than one mutation is involved, and as JAK2 has a necessary physiological role (unlike BCR-ABL), the development of targeted therapy ...
Amy, Publicover, Patrick, Medd
openaire   +3 more sources

Genetic insights into myeloproliferative neoplasms and unusual sites thrombosis. [PDF]

Ann Hematol
Morsia E, Ranalli P, Baldoni S, Mancini S, Morè S, Cantò C, Lame D, Barba G, Poloni A, Rupoli S, Di Ianni M.   +10 more
europepmc   +3 more sources

Myeloproliferative Neoplasms [PDF]

JAMA Oncology, 2015
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-negative myeloproliferative neoplasms and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; respective frequencies of these mutations are ...
Ayalew, Tefferi, Animesh, Pardanani
openaire   +3 more sources

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]

, 2018
Raajit K. Rampal, John Mascarenhas, Heidi Kosiorek, Leah Price, Dmitriy Berenzon, Elizabeth O. Hexner, Camille N. Abboud, Marina Kremyanskaya, Rona Singer Weinberg, Mohamed E. Salama, Kamal Menghrajani, Vesna Najfeld, Lonette Sandy, Mark Heaney, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck, Judith D. Goldberg, Ronald Hoffman   +18 more
openalex   +4 more sources

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2

Biomarker Research, 2021
Eosinophilia represents a group of diseases with heterogeneous pathobiology and clinical phenotypes. Among the alterations found in primary Eosinophilia, gene fusions involving PDGFRα, PDGFRβ, FGFR1 or JAK2 represent the biomarkers of WHO-defined ...
Simone Romagnoli, Niccolò Bartalucci, Francesca Gesullo, Manjola Balliu, Stefania Bonifacio, Anair Graciela Lema Fernandez, Francesco Mannelli, Davide Bolognini, Elisabetta Pelo, Cristina Mecucci, Paola Guglielmelli, Alessandro Maria Vannucchi   +11 more
doaj   +1 more source

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis

Blood Cancer Journal, 2021
Arterial (AT) and venous (VT) thrombotic events are the most common complications in patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality.
Paola Guglielmelli, Giuseppe G. Loscocco, Carmela Mannarelli, Elena Rossi, Francesco Mannelli, Francesco Ramundo, Giacomo Coltro, Silvia Betti, Chiara Maccari, Sara Ceglie, Patrizia Chiusolo, Chiara Paoli, Tiziano Barbui, Ayalew Tefferi, Valerio De Stefano, Alessandro M. Vannucchi   +15 more
doaj   +1 more source

Genomics of Myeloproliferative Neoplasms [PDF]

Journal of Clinical Oncology, 2017
Myeloproliferative neoplasms (MPNs) are a group of related clonal hematologic disorders characterized by excess accumulation of one or more myeloid cell lineages and a tendency to transform to acute myeloid leukemia. Deregulated JAK2 signaling has emerged as the central phenotypic driver of BCR -ABL1–negative MPNs and a unifying therapeutic target. In
Zoi, Katerina, Cross, Nicholas
openaire   +3 more sources